Chemically dimerized intravenous immunoglobulin has potent ameliorating activity in a mouse immune thrombocytopenic purpura model

Biochemical and Biophysical Research Communications

Volumn 418, Issue 4, 2012, Pages 748-753

  Machino, Yusuke ^a   Suzuki, Emiko ^a   Higurashi, Saki ^a   Ohta, Hiroto ^a   Suzuki, Mami ^a   Kohroki, Junya ^a,b   Masuho, Yasuhiko ^a  

^a TOKYO UNIVERSITY OF SCIENCE   (Japan)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Chemical dimerization; Fc gamma receptor; Immune thrombocytopenic purpura; Intravenous immunoglobulin; Platelet

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN; THROMBOCYTE ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; CROSS LINKING; DIMERIZATION; DRUG CONJUGATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING;

ANIMALS; ANTIGENS; CROSS-LINKING REAGENTS; DISEASE MODELS, ANIMAL; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MALE; MICE; MICE, INBRED BALB C; PROTEIN MULTIMERIZATION; PURPURA, THROMBOCYTOPENIC; RECEPTORS, IGG;

EID: 84862829830     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.01.092     Document Type: Article

References (23)

1. Vermeulen M., van der Meché F.G., Speelman J.D., Weber A., Busch H.F. Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy. J. Neurol. Sci. 1985, 70:317-326.
2. Kleyweg R.P., van der Meché F.G., Meulstee J. Treatment of Guillain-Barré syndrome with high-dose gammaglobulin. Neurology 1988, 38:1639-1641.
3. Imbach P., Barandun S., d'Apuzzo V., Baumgartner C., Hirt A., Morell A., Rossi E., Schöni M., Vest M., Wagner H.P. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981, 1:1228-1231.
4. Semple J.W. Immune pathophysiology of autoimmune thrombocytopenic purpura. Blood Rev. 2002, 16:9-12.
5. Bussel J.B. Fc receptor blockade and immune thrombocytopenic purpura. Semin. Hematol. 2000, 37:261-266.
6. Okitsu-Negishi S., Furusawa S., Kawa Y., Hashira S., Ito S., Hiruma F., Mizoguchi M., Yoshino K., Abe T. Suppressive effect of intravenous immunoglobulins on the activity of interleukin-1. Immunol. Res. 1994, 13:49-55.
7. Buchwald B., Ahangari R., Weishaupt A., Toyka K.V. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome. Ann. Neurol. 2002, 51:673-680.
8. Basta M., Van Goor F., Luccioli S., Billings E.M., Vortmeyer A.O., Baranyi L., Szebeni J., Alving C.R., Carroll M.C., Berkower I., Stojilkovic S.S., Metcalfe D.D. F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: A novel effector function of immunoglobulins. Nat. Med. 2003, 9:431-438.
9. Samuelsson A., Towers T.L., Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001, 291:484-486.
10. Debré M., Bonnet M.C., Fridman W.H., Carosella E., Philippe N., Reinert P., Vilmer E., Kaplan C., Teillaud J.L., Griscelli C. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 1993, 342:945-949.
11. Daëron M. Fc receptor biology. Annu. Rev. Immunol. 1997, 15:203-234.
12. Takai T. Roles of Fc receptors in autoimmunity. Nat. Rev. Immunol. 2002, 2:580-592.
13. Léonard S., Pierard I., Michaelsen T.E., Izui S., Masson P.L., Coutelier J.P. Variability of the inhibition by total immunoglobulin of in vitro autoantibody-mediated erythrophagocytosis by mouse macrophages. Clin. Exp. Immunol. 2006, 145:155-161.
14. Siragam V., Crow A.R., Brinc D., Song S., Freedman J., Lazarus A.H. Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat. Med. 2006, 12:688-692.
15. Machino Y., Ohta H., Suzuki E., Higurashi S., Tezuka T., Nagashima H., Kohroki J., Masuho Y. Effect of immunoglobulin G (IgG) interchain disulfide bond cleavage on efficacy of intravenous immunoglobulin for immune thrombocytopenic purpura (ITP). Clin. Exp. Immunol. 2010, 162:415-424.
16. Pendergrast J.M., Sher G.D., Callum J.L. Changes in intravenous immunoglobulin prescribing patterns during a period of severe product shortages, 1995-2000. Vox Sang. 2005, 89:150-160.
17. Teeling J.L., Jansen-Hendriks T., Kuijpers T.W., de Haas M., van de Winkel J.G., Hack C.E., Bleeker W.K. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 2001, 98:1095-1099.
18. Wymann S., Ghielmetti M., Schaub A., Baumann M.J., Stadler B.M., Bolli R., Miescher S.M. Monomerization of dimeric IgG of intravenous immunoglobulin (IVIg) increases the antibody reactivity against intracellular antigens. Mol. Immunol. 2008, 45:2621-2628.
19. Hiemstra P.S., Brands-Tajouiti J., van Furth R. Comparison of antibody activity against various microorganisms in intravenous immunoglobulin preparations determined by ELISA and opsonic assay. J. Lab. Clin. Med. 1994, 123:241-246.
20. Tinguely C., Schaller M., Nydegger U.E. Mononuclear cells ingest E. coli opsonized by investigational intravenous immunoglobulin preparations in the absence of complement more efficiently than polymorphonuclear phagocytes. Transfus. Apher. Sci. 2001, 25:43-50.
21. Bazin R., Lemieux R., Tremblay T., St-Amour I. Tetramolecular immune complexes are more efficient than IVIg to prevent antibody-dependent in vitro and in vivo phagocytosis of blood cells. Br. J. Haematol. 2004, 127:90-96.
22. Siragam V., Brinc D., Crow A.R., Song S., Freedman J., Lazarus A.H. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?. J. Clin. Invest. 2005, 115:155-160.
23. Xiao J., Hamilton B.S., Tolbert T.J. Synthesis of N-terminally linked protein and peptide dimers by native chemical ligation. Bioconj. Chem. 2010, 21:1943-1947.